The global oncology biosimilar market is witnessing strong growth driven by increasing cancer prevalence and rising demand for cost-effective biologic therapies. According to the latest market analysis, the global oncology biosimilar market was valued at USD 5.21 billion in 2024 and is projected to grow from USD 5.94 billion in 2025 to USD 14.87 billion by 2033, registering a CAGR of 14.2% during the forecast period (2025–2033).
Oncology biosimilars are biologic medical products highly similar to already approved reference biologics, offering comparable efficacy and safety at reduced costs, thereby improving patient access to cancer treatments.
Key Highlights
- Base Year: 2024
- Forecast Period: 2025–2033
- Market Size 2024: USD 5.21 Billion
- Market Size 2033: USD 14.87 Billion
- CAGR: 14.2%
- Largest Region: Europe
- Fastest Growing Region: Asia-Pacific (CAGR of 15.1%)
- Largest Segment (Drug Class): Monoclonal Antibodies
- Fastest Growing Segment: Monoclonal Antibodies
- Largest Segment (Indication): Breast Cancer
- Fastest Growing Segment: Lung Cancer
Market Dynamics
Drivers
The global oncology biosimilar market is primarily driven by the increasing prevalence of cancer worldwide and the rising cost burden associated with biologic therapies. Biosimilars provide a cost-effective alternative to expensive branded biologics, making cancer treatment more accessible to a larger patient population. Governments and healthcare systems are actively promoting the adoption of biosimilars to reduce healthcare expenditure and improve treatment accessibility.
Additionally, the expiration of patents for several blockbuster biologic drugs has opened the door for biosimilar development and commercialization. Increasing investments in research and development, along with favorable regulatory frameworks in several regions, are further supporting market growth.
Restraints and Opportunities
Despite strong growth potential, the market faces challenges such as stringent regulatory requirements and concerns regarding the interchangeability of biosimilars with reference biologics. The complex manufacturing process and high development costs associated with biosimilars can also act as barriers for new entrants.
However, these challenges present opportunities for innovation and expansion. Growing awareness among healthcare professionals and patients about the benefits of biosimilars is expected to drive adoption. Moreover, increasing investments in emerging markets, along with advancements in biotechnology and manufacturing processes, are anticipated to create significant growth opportunities for market players in the coming years.
Top Market Players
- Amgen Inc.
- Pfizer Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Biocon Limited
- Celltrion Inc.
- Samsung Bioepis
- Dr. Reddy’s Laboratories Ltd.
- Fresenius Kabi AG
Request Sample Report of Global Market @ https://straitsresearch.com/report/oncology-biosimilar-market/request-sample
Market Segmentation
By Drug Class
- Monoclonal Antibodies
- Granulocyte Colony-Stimulating Factors (G-CSF)
- Erythropoietin Stimulating Agents
By Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Blood Cancer
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia-Pacific
- Middle East and Africa
- Latin America
About Us
Straits Research is a leading market research and market intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & market research reports.
Contact Us
Email: sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
